Christian Labenz1,2, Yvonne Huber1,2, Maurice Michel1,2, Michael Nagel1,2, Peter R Galle1,2, Karel Kostev3, Jörn M Schattenberg4,5. 1. Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131, Mainz, Germany. 2. Metabolic Liver Research Program, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany. 3. Epidemiology, IQVIA, Frankfurt, Germany. 4. Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131, Mainz, Germany. joern.schattenberg@unimedizin-mainz.de. 5. Metabolic Liver Research Program, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany. joern.schattenberg@unimedizin-mainz.de.
Abstract
BACKGROUND: Patients with NAFLD are considered at a high risk of cardiovascular events due to underlying metabolic risk factors. Currently, data related to the impact of NAFLD on cardiovascular risk in the general population are lacking. AIMS: The aim of this study was to investigate the role of NAFLD on risk of myocardial infarction (MI), coronary heart disease (CHD), atrial fibrillation (AF), and stroke in primary care in Germany. METHODS: The study included patients diagnosed with NAFLD in primary care between 2010 and 2015. NAFLD cases (n = 22,048) were matched to a cohort without NAFLD (n = 22,048) based on age, sex, treating physician, type 2 diabetes, arterial hypertension, and hyperlipidemia. The primary outcome of the study was the incidence of MI, CHD, AF, and stroke. RESULTS: Within 10 years of the index date, 12.8% of patients with NAFLD and 10.0% of controls were diagnosed with CHD (p < 0.001). Additionally, frequency of MI was significantly higher in NAFLD (2.9% vs. 2.3%, p < 0.001). On regression analysis, HR for incidence of MI was 1.34 (p = 0.003) in all NAFLD patients and 1.35 (p = 0.013) for men. Incidence of AF was significantly higher in patients with NAFLD. On regression analysis, HR for incidence of AF was 1.15 (p = 0.005). NAFLD was not associated with a higher incidence of stroke (HR 1.09, p = 0.243). CONCLUSIONS: NAFLD constitutes an independent risk factor for CHD, MI, and AF in primary care in Germany. Identification of patients with NAFLD in primary care will allow specifically managing and modifying underlying risk factors to improve the overall prognosis.
BACKGROUND:Patients with NAFLD are considered at a high risk of cardiovascular events due to underlying metabolic risk factors. Currently, data related to the impact of NAFLD on cardiovascular risk in the general population are lacking. AIMS: The aim of this study was to investigate the role of NAFLD on risk of myocardial infarction (MI), coronary heart disease (CHD), atrial fibrillation (AF), and stroke in primary care in Germany. METHODS: The study included patients diagnosed with NAFLD in primary care between 2010 and 2015. NAFLD cases (n = 22,048) were matched to a cohort without NAFLD (n = 22,048) based on age, sex, treating physician, type 2 diabetes, arterial hypertension, and hyperlipidemia. The primary outcome of the study was the incidence of MI, CHD, AF, and stroke. RESULTS: Within 10 years of the index date, 12.8% of patients with NAFLD and 10.0% of controls were diagnosed with CHD (p < 0.001). Additionally, frequency of MI was significantly higher in NAFLD (2.9% vs. 2.3%, p < 0.001). On regression analysis, HR for incidence of MI was 1.34 (p = 0.003) in all NAFLD patients and 1.35 (p = 0.013) for men. Incidence of AF was significantly higher in patients with NAFLD. On regression analysis, HR for incidence of AF was 1.15 (p = 0.005). NAFLD was not associated with a higher incidence of stroke (HR 1.09, p = 0.243). CONCLUSIONS: NAFLD constitutes an independent risk factor for CHD, MI, and AF in primary care in Germany. Identification of patients with NAFLD in primary care will allow specifically managing and modifying underlying risk factors to improve the overall prognosis.
Authors: Yvonne Huber; Christian Labenz; Maurice Michel; Marcus-A Wörns; Peter R Galle; Karel Kostev; Jörn M Schattenberg Journal: Dtsch Arztebl Int Date: 2020-10-23 Impact factor: 5.594
Authors: Laurens A van Kleef; Ibrahim Ayada; Louise J M Alferink; Qiuwei Pan; Robert J de Knegt Journal: Hepatology Date: 2021-12-13 Impact factor: 17.298
Authors: Leonard Kaps; Christian Labenz; Peter R Galle; Julia Weinmann-Menke; Karel Kostev; Jörn M Schattenberg Journal: United European Gastroenterol J Date: 2020-07-23 Impact factor: 4.623
Authors: Sven H Loosen; Christoph Roderburg; Ole Curth; Julia Gaensbacher; Markus Joerdens; Tom Luedde; Marcel Konrad; Karel Kostev; Mark Luedde Journal: Sci Rep Date: 2022-02-17 Impact factor: 4.379
Authors: Christian Labenz; Karel Kostev; Angelo Armandi; Peter R Galle; Jörn M Schattenberg Journal: United European Gastroenterol J Date: 2021-07-20 Impact factor: 6.866